Related references
Note: Only part of the references are listed.Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta-Analysis
Erin Wolf et al.
HEPATOLOGY (2021)
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Josep M. Llovet et al.
HEPATOLOGY (2021)
Patient-Reported Barriers Are Associated With Receipt of Hepatocellular Carcinoma Surveillance in a Multicenter Cohort of Patients With Cirrhosis
Amit G. Singal et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis
Andrew M. Moon et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: Expert Review
Rohit Loomba et al.
GASTROENTEROLOGY (2020)
Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis
Nicole E. Rich et al.
HEPATOLOGY (2020)
Advances in molecular classification and precision oncology in hepatocellular carcinoma
Sandra Rebouissou et al.
JOURNAL OF HEPATOLOGY (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms
Neehar D. Parikh et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma
Nicole E. Rich et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Generic chemoprevention of hepatocellular carcinoma
Sai Krishna Athuluri-Divakar et al.
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES (2019)
Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial
Roser Pinyol et al.
GUT (2019)
Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma
Michael Teufel et al.
GASTROENTEROLOGY (2019)
Hepatocellular Carcinoma
Augusto Villanueva
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials
Robert Montal et al.
BRITISH JOURNAL OF CANCER (2019)
Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores
George N. Ioannou et al.
GASTROENTEROLOGY (2019)
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
Richard D. Kim et al.
CANCER DISCOVERY (2019)
Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis
Hooman Farhang Zangneh et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease
Luis Calzadilla Bertot et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2019)
Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma
Ho Yeong Lim et al.
CLINICAL CANCER RESEARCH (2018)
Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis
Kristina Tzartzeva et al.
GASTROENTEROLOGY (2018)
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
Jorge A. Marrero et al.
HEPATOLOGY (2018)
Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine
Naoto Fujiwara et al.
JOURNAL OF HEPATOLOGY (2018)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration
Willi Sauerbrei et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
Lorenza Rimassa et al.
LANCET ONCOLOGY (2018)
A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma
Ismail Labgaa et al.
ONCOGENE (2018)
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration
Willi Sauerbrei et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis
Nathalie Ganne-Carrie et al.
JOURNAL OF HEPATOLOGY (2018)
Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis
O. Simmons et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
An Assessment of Benefits and Harms of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis
Omair Atiq et al.
HEPATOLOGY (2017)
Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)
M. J. Duffy et al.
EUROPEAN JOURNAL OF CANCER (2017)
Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer
Douglas J. Robertson et al.
GASTROENTEROLOGY (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma
Lorenza Rimassa et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Cost-Effectiveness of Risk Score-Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis
Nicolas Goossens et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2017)
Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma Analysis of REACH Trial Results by Child-Pugh Score
Andrew X. Zhu et al.
JAMA ONCOLOGY (2017)
Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans Is Associated With Nonalcoholic Fatty Liver Disease
Sahil Mittal et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients
Sarah Berhane et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Genetic profiling of hepatocellular carcinoma using next-generation sequencing
Kornelius Schulze et al.
JOURNAL OF HEPATOLOGY (2016)
FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1
Joohee Sul et al.
ONCOLOGIST (2016)
Genetic Landscape and Biomarkers of Hepatocellular Carcinoma
Jessica Zucman-Rossi et al.
GASTROENTEROLOGY (2015)
Liver resection for hepatocellular carcinoma in 313 Western patients: Tumor biology and underlying liver rather than tumor size drive prognosis
Michael D. Kluger et al.
JOURNAL OF HEPATOLOGY (2015)
Prognostic and Predictive Biomarkers: Tools in Personalized Oncology
Ewelina Nalejska et al.
MOLECULAR DIAGNOSIS & THERAPY (2014)
A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection
Jean-Charles Nault et al.
GASTROENTEROLOGY (2013)
Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
Josep M. Llovet et al.
CLINICAL CANCER RESEARCH (2012)
Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan Criteria
Christophe Duvoux et al.
GASTROENTEROLOGY (2012)
Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma
Silvia Tremosini et al.
GUT (2012)
Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses
Jean-Luc Raoul et al.
JOURNAL OF HEPATOLOGY (2012)
Gene Signatures in the Management of Hepatocellular Carcinoma
Yujin Hoshida et al.
SEMINARS IN ONCOLOGY (2012)
Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular Carcinoma
Augusto Villanueva et al.
GASTROENTEROLOGY (2011)
Feasibility of Conducting a Randomized Control Trial for Liver Cancer Screening: Is a Randomized Controlled Trial for Liver Cancer Screening Feasible or Still Needed?
Hossein Poustchi et al.
HEPATOLOGY (2011)
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Edward S. Kim et al.
CANCER DISCOVERY (2011)
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group
Steven M. Teutsch et al.
GENETICS IN MEDICINE (2009)
Pathologic Diagnosis of Early Hepatocellular Carcinoma: A Report of the International Consensus Group for Hepatocellular Neoplasia
Masamichi Kojiro et al.
HEPATOLOGY (2009)
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Richard M. Simon et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
EpCAM and α-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma
Taro Yamashita et al.
CANCER RESEARCH (2008)
Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design
Margaret S. Pepe et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma
Yujin Hoshida et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis
Luca Di Tommaso et al.
HEPATOLOGY (2007)
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis
Josep M. Llovet et al.
GASTROENTEROLOGY (2006)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Clinical trial designs for predictive marker validation in cancer treatment trials
DJ Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
